DR. BARRY ZINGMAN, LEADING REMDESIVIR DRUG TRIAL BACKED BY NIH: But the information that we have so far is very strong that people are being discharged about four days earlier, and that the mortality difference is very strongly in favor of remdesivir being also about 30 percent less, which is a very sig -- very significant. And -- and I wouldn't be surprised if as the data is analyzed further, that subgroups from the thousand patients are identified in whom it's even clearer, but that awaits further analyses.</s>JAKE TAPPER, CNN HOST: If studies -- if studies such as yours show that this is an effective treatment, how soon, theoretically, would this be available for patients?</s>ZINGMAN: So, my understanding is that Gilead is working with the FDA to make this available as soon as possible. It is available right now through clinical trials, it's available through what's called Expanded Access Protocols and then the emergency use authorization that is being worked on between Gilead and FDA is coming in the next few weeks. So we do think that there are going to be multiple ways to get remdesivir over the next few weeks. And that will improve and improve and improve as the weeks and months go by.</s>TAPPER: All right. Well, Dr. Barry Zingman, we wish you all the best with your trial. Thank you so much, and thanks for -- thanks for the work you do. We really appreciate it.</s>ZINGMAN: Thank you so much for covering this. This is a really important advance.</s>TAPPER: Yes. Well, fingers crossed. Hope it goes exactly as you want it to. Coming up, in a matter of weeks, one in five Americans has lost his or her jobs, 30 million people. We're going to talk with a Nobel Prize-winning economist who has a plan to re-open the nation responsibly. That's next. Stay with us.
Dr. Fauci Expects the Drug Remdesivir Will Be Approved for Emergency Use "Very Quickly"